European Immunology

Immune Cell Reprogramming & Gene-Edited Immunotherapies

Advances in immune cell engineering are reshaping the therapeutic landscape by enabling precise manipulation of T cells, NK cells and dendritic cells to improve safety, specificity and long-term efficacy. Gene-editing platforms such as CRISPR, base editors and epigenome modulators now allow clinicians to reprogram immune cells to better recognize tumor antigens, resist immunosuppressive microenvironments and enhance persistence in circulation. These engineered cells are being tailored with synthetic receptors, armored gene circuits and controlled cytokine outputs to reduce toxicities and prevent immune exhaustion. Research continues to expand beyond CAR-T cells to include CAR-NK, CAR-macrophages, TCR-T cells and hybrid synthetic immune constructs capable of coordinated multi-target responses. Applications extend from oncology to autoimmunity, infectious diseases and transplant rejection. The integration of AI-driven antigen prediction, high-throughput functional screening and in vivo genome delivery technologies is accelerating the development of customizable immune products. This approach aims to build a new generation of intelligent, adaptable therapeutics capable of precise pathogen clearance, durable anti-tumor immunity and restoration of immunological balance across diverse patient populations.